Hsa_circ_0096157 silencing suppresses autophagy and reduces cisplatin resistance in non-small cell lung cancer by weakening the Nrf2/ARE signaling pathway
- PMID: 38822881
- DOI: 10.1007/s11033-024-09552-z
Hsa_circ_0096157 silencing suppresses autophagy and reduces cisplatin resistance in non-small cell lung cancer by weakening the Nrf2/ARE signaling pathway
Abstract
Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer morbidity and mortality worldwide, and new diagnostic markers are urgently needed. We aimed to investigate the mechanism by which hsa_circ_0096157 regulates autophagy and cisplatin (DDP) resistance in NSCLC.
Methods: A549 cells were treated with DDP (0 μg/mL or 3 μg/mL). Then, the autophagy activator rapamycin (200 nm) was applied to the A549/DDP cells. Moreover, hsa_circ_0096157 and Nrf2 were knocked down, and Nrf2 was overexpressed in A549/DDP cells. The expression of Hsa_circ_0096157, the Nrf2/ARE pathway-related factors Nrf2, HO-1, and NQO1, and the autophagy-related factors LC3, Beclin-1, and p62 was evaluated by qRT‒PCR or western blotting. Autophagosomes were detected through TEM. An MTS assay was utilized to measure cell proliferation. The associated miRNA levels were also tested by qRT‒PCR.
Results: DDP (3 μg/mL) promoted hsa_circ_0096157, LC3 II/I, and Beclin-1 expression and decreased p62 expression. Knocking down hsa_circ_0096157 resulted in the downregulation of LC3 II/I and Beclin-1 expression, upregulation of p62 expression, and decreased proliferation. Rapamycin reversed the effect of interfering with hsa_circ_0096157. Keap1 expression was lower, and Nrf2, HO-1, and NQO1 expression was greater in the A549/DDP group than in the A549 group. HO-1 expression was repressed after Nrf2 interference. In addition, activation of the Nrf2/ARE pathway promoted autophagy in A549/DDP cells. Moreover, hsa_circ_0096157 activated the Nrf2/ARE pathway. The silencing of hsa_circ_0096157 reduced Nrf2 expression by releasing miR-142-5p or miR-548n. Finally, we found that hsa_circ_0096157 promoted A549/DDP cell autophagy by activating the Nrf2/ARE pathway.
Conclusion: Knockdown of hsa_circ_0096157 inhibits autophagy and DDP resistance in NSCLC cells by downregulating the Nrf2/ARE signaling pathway.
Keywords: Autophagy; Cisplatin; Hsa_circ_0096157; Non-small cell lung cancer; Nrf2/ARE signaling pathway.
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Similar articles
-
Baicalin promotes the sensitivity of NSCLC to cisplatin by regulating ferritinophagy and macrophage immunity through the KEAP1-NRF2/HO-1 pathway.Eur J Med Res. 2024 Jul 26;29(1):387. doi: 10.1186/s40001-024-01930-4. Eur J Med Res. 2024. PMID: 39061086 Free PMC article.
-
Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.Mol Cell Biochem. 2020 Dec;475(1-2):63-77. doi: 10.1007/s11010-020-03860-1. Epub 2020 Aug 6. Mol Cell Biochem. 2020. PMID: 32767026
-
DICER activates autophagy and promotes cisplatin resistance in non-small cell lung cancer by binding with let-7i-5p.Acta Histochem. 2021 Oct;123(7):151788. doi: 10.1016/j.acthis.2021.151788. Epub 2021 Sep 17. Acta Histochem. 2021. PMID: 34543777
-
miR-29b-3p targetedly regulates VEGF to inhibit tumor progression and cisplatin resistance through Nrf2/HO-1 signaling pathway in non-small cell lung cancer.Environ Toxicol. 2024 Jul;39(7):3956-3966. doi: 10.1002/tox.24253. Epub 2024 Apr 8. Environ Toxicol. 2024. PMID: 38587027
-
Knockdown of TRIM65 inhibits autophagy and cisplatin resistance in A549/DDP cells by regulating miR-138-5p/ATG7.Cell Death Dis. 2019 Jun 3;10(6):429. doi: 10.1038/s41419-019-1660-8. Cell Death Dis. 2019. PMID: 31160576 Free PMC article.
Cited by
-
Recent advances in the role of circRNA in cisplatin resistance in tumors.Cancer Gene Ther. 2025 May;32(5):497-506. doi: 10.1038/s41417-025-00899-4. Epub 2025 Mar 27. Cancer Gene Ther. 2025. PMID: 40148680 Review.
-
The potential of targeting autophagy-related non-coding RNAs in the treatment of lung cancer.Front Pharmacol. 2025 May 14;16:1551258. doi: 10.3389/fphar.2025.1551258. eCollection 2025. Front Pharmacol. 2025. PMID: 40438586 Free PMC article. Review.
-
Jumonji domain-containing protein 6 promotes gastric cancer progression: Modulating immune evasion through autophagy and oxidative stress pathways.Cytojournal. 2025 Jan 23;22:6. doi: 10.25259/Cytojournal_230_2024. eCollection 2025. Cytojournal. 2025. PMID: 39958885 Free PMC article.
References
-
- Cascone T et al (2022) Tumor immunology and immunotherapy of non-small-cell lung cancer. Cold Spring Harb Perspect Med. https://doi.org/10.1101/cshperspect.a037895 - DOI - PMC - PubMed
-
- Song S et al (2023) circANKRD28 inhibits cisplatin resistance in non-small-cell lung cancer through the miR-221-3p/SOCS3 axis. J Gene Med. https://doi.org/10.1002/jgm.3478 - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous